Is Wanbury overvalued or undervalued?

As of 12 June 2025, Wanbury's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued, with a PE ratio of 32.29, an EV to EBITDA of 15.43, and a ROE of 51.53%. In comparison to its peers, Sun Pharma has a higher PE ratio of 35.4 and an EV to EBITDA of 25.02, while Cipla is more attractively valued with a PE ratio of 23.01 and an EV to EBITDA of 15.95.
The strong performance of Wanbury is further highlighted by its impressive return metrics, including a 1-year return of 94.00%, significantly outpacing the Sensex's 6.64% return over the same period. This performance reinforces the notion that Wanbury is well-positioned within the pharmaceuticals and biotechnology sector, making it an appealing investment at its current valuation.